Mutation of K-Ras is a frequent oncogenic event in human cancers, particularly cancers of lungs, pancreas, and colon. It remains unclear why some tissues are more susceptible to Ras-induced transformation than others. Here, we globally activated a mutant oncogenic K-Ras allele (K-Ras G12D ) in mice and examined the tissue-specific effects of this activation on cancer pathobiology, Ras signaling, tumor suppressor, DNA damage, and inflammatory responses. Within 5 to 6 weeks of oncogenic Ras activation, mice develop oral and gastric papillomas, lung adenomas, and hematopoietic hyperproliferation and turn moribund. The oral, gastric, and lung premalignant lesions display activated extracellular signal-regulated kinases (Erk)1/2 and NF-kB signaling as well as activated tumor suppressor and DNA damage responses. Other organs such as pancreas, liver, and small intestine do not exhibit neoplastic progression within 6 weeks following K-Ras G12D activation and do not show a potent tumor suppressor response. Even though robust Erk1/2 signaling is activated in all the tissues examined, the pErk1/2 distribution remains largely cytoplasmic in K-Ras
Introduction
The evolution of a cancer cell is accompanied by the dysregulation of growth signaling pathways that are often the result of altered structure or expression of proto-oncogenes or tumor suppressor genes (1) . Among the most frequently mutated proto-oncogenes in human cancers are the Ras family of small GTPases. Ras isoforms are mutated in approximately 30% of human cancers, leading to dysregulation of cellular proliferative functions. Of the 3 oncogenic Ras alleles, K-Ras, H-Ras, and N-Ras, K-Ras is the most frequently mutated isoform in human cancers (2) (3) (4) . Oncogenic K-Ras-induced neoplasms result in part from constitutive activation of Ras/Raf/MAPK (mitogen-activated protein kinase) signaling that leads to uncontrolled proliferation. Key downstream targets in Ras signaling are extracellular signal-regulated kinases (Erk1/2), MAPKs that are phosphorylated by the Ras-activated Raf, and MEK kinases (5) . Phosphorylated Erks (pErk1/2) efficiently translocate to the nucleus via a noncanonical nuclear localization signal (6) (7) (8) . In the nucleus, pErk1/2 phosphorylate and activate a number of transcription factors such as Elk-1 and c-Myc that induce genes important for cell proliferation. The nuclear translocation of pErk1/2, which is rapid and reversible, is critical for the activation of growth factor-induced mitogenic signaling (9) (10) (11) (12) (13) . The pErks also phosphorylate a number of cytoplasmic substrates, some of which provide a negative feedback loop to the Erk pathway (14) . A number of studies in cell lines have shown that spatial regulation of Erks control their function. However, clear in vivo correlates of differential Erk subcellular distribution and tumorigenic outcome have been lacking.
Despite the association of Ras mutations with human cancers such as pancreatic, colon, and lung carcinoma, other tumor types are largely devoid of Ras lesions (2) (3) (4) . Moreover, genetically programmed Ras activation in mice shows variable efficacy in inducing rapid neoplasias that are, in part, tissue-dependent (15) (16) (17) (18) . It remains largely unclear why some tissues are susceptible to oncogenic K-Rasinduced tumors whereas other tissues remain refractory. Some oncogenic K-Ras mouse models revealed induction of tumor suppressors such as p16
Ink4a and p19 Arf in earlystage lesions (19, 20) , presumably as a key defense mechanism that blocks further progression of the premalignant tumors to malignant tumors. However, the robustness of the tumor suppressor response may depend on many variables, including, but not limited to, the type of tissue, lesion, and nature of oncogenic stimulus (21) (22) (23) (24) . For example, the Ink4a/Arf (Cdkn2a) locus was found to be repressed in K-Ras G12D -induced lung tumors in contrast to K-Ras G12D -induced sarcomas in mice (21) . Another component of the anti-oncogenic response may be provided by activation of the DNA damage response (DDR) pathway (25, 26) . The DDR is believed to be induced by DNA replication stress that promotes antiproliferative responses such as cell-cycle arrest, senescence, or apoptosis (26) . Recent mouse cancer models have also implicated NF-kB signaling as an important component of the Rasinitiated premalignant lesions, a chemotherapeutic target or a promoter of senescence (27) (28) (29) . Thus, the outcome of oncogene-induced hyperproliferation may depend on the interplay between oncogenic signaling and tumor suppressor pathways.
Understanding the mechanisms by which certain mutational events promote cancer phenotypes in some tissues but not in others remains a major challenge and requires systematic analyses. To investigate the response of different tissues to an oncogenic stimulus, we crossed Rosa26-Cre-ERT2 and LSL-K-Ras G12D mouse lines to generate biallelic progeny that allowed us to conditionally induce an activated form of K-Ras (K-Ras G12D ) in adult mouse tissues in a global manner. We examined the pathobiology of tumor formation in multiple tissues and used molecular approaches to examine the tissue-specific differences in the activated signaling pathways. Activation of mutant K-Ras led to potent Ras signaling in most mouse tissues within 1 week. Mice developed oral, gastric, and lung neoplastic lesions along with myeloproliferative disease and leukemia within 4 weeks and were moribund by 6 weeks. However, despite exhibiting activated Ras signaling, tissues such as liver, intestine, and pancreas failed to display significant cancer-related pathobiology in the 6-week time period following K-Ras G12D activation. Interestingly, these K-Ras-refractory tissues upregulated the Ras downstream target phospho-Erk1/2 but retained it primarily in the cytoplasm, in contrast to oncogenic K-Ras-induced neoplasms where pErk1/2 distribution was largely nuclear. Also, in contrast to K-Ras G12D -susceptible tissues, there was minimal detection of the pErk1/2 nuclear targets phospho-Elk-1 and c-Myc in KRas G12D -refractory tissues. Robust activation of tumor suppressor, DDR pathways, and NF-kB signaling was observed in the K-Ras G12D -susceptible premalignant tumors. In contrast, tumor suppressor responses were not noted in the Ras refractory tissues. In the mouse model of K-Ras G12D activation presented here, the restriction of pErk1/2 signaling may represent a critical failsafe mechanism that protects some tissues from developing Rasinduced early preneoplastic lesions. Such a mechanism may explain some of the tissue-specific differences in susceptibility to Ras transformation.
Materials and Methods

Mice
B6.129 background LSL-K-Ras G12D mice (donated by Dr. Tyler Jacks, Massachusetts Institute of Technology, Cambridge, MA) were obtained from the National Cancer Institute Mouse Models of Human Cancers Consortium Repository. These mice were crossed into C57BL/6 Cre-ERT2 mice obtained from Artemis Pharmaceuticals GmbH (30) . All mice were bred and maintained in a specific pathogen-free animal facility at Baylor College of Medicine (Houston, TX). All research with mice was conducted in compliance with the Baylor Animal Protocol Committee (Baylor College of Medicine Animal Protocol AN336) and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) recommendations as published in The Guide for the Care and Use of Laboratory Animals (NRC1996).
Allele genotyping
Genomic DNA was prepared from 5-mm tail tips or 50 mg tissue as described (31) . The presence of the Cre-ERT2 gene was verified using the primers Cre-F: 5 0 -AAG AAC CTG ATG GAC ATG TTC AGG G-3 0 and Cre-R: 5 0 -CCA GAC CAG GCC AGG TAT CTC T-3 0 , which produce a 790-bp product following standard PCR. Genotyping for the LSL-K-Ras G12D allele was carried out using the forward primer, 5 0 AGC TAG CCA CCA TGG CTT GAG TAA GTC TGC 3 0 and reverse primer 5 0 CCT TTA CAA GCG CAC GCA GAC TGT AGA 3 0 giving a 550-bp PCR product for the LSL allele. PCR analysis to detect Cremediated recombination in various tissues was carried out with the primers forward 5 0 GTC TTT CCC CAG CAC AGT GC 3 0 and reverse 5 0 CTC TTG CCT ACG CCA CCA GCT C 3 0 . These primers amplify the wild-type K-Ras ($620 bp) and LoxP-recombined K-Ras G12D allele ($650 bp). LSL-K-Ras G12D is too big ($6 kb) to be amplified under the conditions used for PCR.
Wild-type and mutant K-Ras allele expression
Total RNA was isolated from tissues using the TRIzol reagent (Life Technologies). RNA expression of wild-type K-Ras and mutant K-Ras G12D was determined as described (32) . Briefly, cDNA was generated and PCR amplified using the One-Step Reverse Transcription PCR Kit (QIAGEN), primers 5 0 GCCATTTCGGACCCGGAGCGA 3 0 and 5 0 CCTACCAGGACCATAGGCACATC 3 0 . The mutant K-Ras G12D allele contains a HindIII restriction site engineered in exon 1, which is absent in the wild-type allele, thus generating 300-bp and 148-bp restriction fragments in the mutant but not in the wild-type 448-bp PCR product.
K-Ras
G12D allele induction Tamoxifen (Sigma-Aldrich) was prepared at a concentration of 10 mg/mL in corn oil. Cre-ERT2 allele-containing mice were injected intraperitoneally with 100 mL tamoxifen solution (1 mg tamoxifen per injection) daily for 5 consecutive days at the ages of 3 to 4 months.
Bromodeoxyuridine injection
Bromodeoxyuridine (BrdUrd) stock (10 mg/mL) was made in sterile PBS and stored in aliquots at À20 C. Mice were intraperitoneally injected with 100 mg BrdUrd/g body weight 5 hours before sacrificing.
Tissue lysate preparation and Western blot analysis
Freshly excised tissue samples were harvested, snap-frozen, and stored at À80 C until use. Approximately 50 mg tissue was homogenized in 500 mL NP-40 lysis buffer: 150 mmol/L NaCl, 50 mmol/L Tris-HCl (pH 7.5), 0.75% NP-40 þ 1 mini EDTA protease inhibitor tablet/10 mL (Roche Applied Science). After an hour of incubation at 4 C, tissue lysates were centrifuged at 12,000 Â g for 10 minutes, and supernatants stored at À80 C until use. For detection of gH2AX, 0.75% NP-40 was replaced with 1% SDS in the lysis buffer and lysates were sonicated 3 times for 10 seconds each with intermittent incubations on ice. Thirty-five to 40 mg tissue lysates were loaded per SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membrane. Blots were incubated with antibodies for pErk1/2 (Cat #4370), Erk1/2 (Cat #4695), pSTAT3 (Cat # 9145), STAT3 (Cat #9139), and pIKKa/b (Cat #2681) from Cell Signaling Technology; p53 (R-19), p21 (M-19 and C-19), p16
Ink4a (M-156), IKKa/b (Cat # sc-7607), and RelA (H-286) from Santa Cruz Biotechnology; p19
Arf (Cat # ab26696) from Abcam; and gH2AX (Cat# 05-636), H2AX (Cat. # 07-627), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Cat #MAB374) from Millipore. Signal was detected using SuperSignal West Pico and Femto Chemiluminescent substrates (Pierce Thermo Fisher scientific).
Histologic analysis and immunohistochemistry
All animals showing overt tumors or other signs of distress were humanely sacrificed and subjected to full necropsy. For histologic analysis, tissues and tumors were fixed in 10% neutral-buffered formalin, paraffin-processed, sectioned at 5 mm, and stained with hematoxylin and eosin (H&E). Immunohistochemistry was conducted using the VECTAS-TAIN ABC Kit Rabbit (Vector Labs Cat #6101), Vector M. O.M. Immunodetection Kit (Vector Labs Cat #2202) and BrdU Detection Kit (BD Biosciences, Cat #550803) as per manufacturer's instructions. Citrate-based Vector Antigen Unmasking Solution (Vector Labs) was used for antigen retrieval. The sections were incubated with following primary antibodies (4 C overnight): anti-pErk1/2, antipSTAT3, anti RelA (Cell Signaling, Cat #4764), anti-RelA (NLS; Millipore, Cat #17-10060), anti-PML (Santa Cruz Biotechnology, Cat #sc-966), anti-pElk-1 (Santa Cruz Biotechnology, Cat #sc-8406), and anti-Ki67 (Vector Labs, Cat #VP-RM04). Vector NovaRED Substrate Kit (Vector Labs, Cat #SK-4800) was used for color development followed by hematoxylin counterstaining.
Immunofluorescence
For immunofluorescence, paraffin sections were blocked at room temperature for 1 hour in a TSA kit blocking buffer (PerkinElmer) and incubated overnight at 4 C or room temperature with the following antibodies: anti-pErk1/2, anti-pSTAT3, anti-p19
Arf , anti-p53 (Novocastra, clone CM5), anti-pATM (Rockland, Cat #200-301-500), anti-p16
Ink4a (Santa Cruz Biotechnology, F-12), and anti-c-Myc (Santa Cruz Biotechnology, Cat # sc-764). The secondary biotinylated antibodies were from Santa Cruz Biotechnology. The immunofluorescence was developed using TSA kits on the basis of the manufacturer's instructions. Ki67 (Vector Labs, Cat #VP-RM04), BrdU (BD Biosciences, Cat # 555627), K5 (Covance, Cat #PRB-160P), K13 (Abcam, Cat #ab16112), and gH2AX proteins were probed using Alexa Fluor-conjugated secondary antibodies (Life Technologies). Sections were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI) and mounted with ProLong Gold Antifade Reagent (Life Technologies).
Microscopy
Bright field images were captured using an inverted microscope (BX50, Olympus) equipped with Olympus DP11 camera. Fluorescent images were captured at Â40 with a Zeiss Axioplan II upright microscope and images processed using MetaVue software version 6.3r7 at the Integrated Microscopy Core facility at Baylor College of Medicine.
Quantitative real-time PCR
Total RNA extracted from mouse tissues was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Life Technologies) as per manufacturer's instructions. Real-time PCR (RT-PCR) was carried out in Corbett Rotor-Gene, RG-3000 thermal cycler (Qiagen) using iQ SYBR Green Supermix (Bio-Rad Laboratories). The following primers designed using Primer-BLAST software were used: IL-6 forward 5 0 . Each sample was tested in replicates and the RT-PCR carried out 2 to 3 times for each sample and primer pair. Differences between tumors and control tissues were normalized to expression of b-actin using the DDC t method.
Results
Mutant Ras is activated in most tissues of Cre-ERT2;KRas G12D mice To achieve global expression of oncogenic K-Ras, we generated Cre-ERT2;K-Ras G12D mice by crossing the knock-in Rosa26-Cre-ERT2 mice with mice carrying a knock-in Lox-Stop-Lox(LSL)-K-Ras G12D allele containing an oncogenic point mutation in exon 1 (G12D; refs. 30, 33) . The Cre-ERT2 allele, which encodes for a tamoxifen-responsive-modified Cre recombinase, is expressed by the ubiquitous Rosa26 promoter, whereas the LSL-K-Ras G12D allele is downstream of the endogenous K-Ras promoter. Administration of tamoxifen induces nuclear translocation of Cre-ERT2 resulting in deletion of the LSL cassette in biallelic Cre-ERT2;LSL-K-Ras G12D mice (Fig. 1A) . All tissues examined other than the brain showed extensive deletion of the LSL cassette following tamoxifen injection in Cre-ERT2;K-Ras G12D mice as assessed by PCR (Fig. 1B) . To test the expression of the K-Ras G12D allele in various tissues, we used reverse transcription PCR followed by HindIII digestion specific for the Ras G12D allele (32). K-Ras G12D mRNA was detected in most tissues, including brain tissue where we did not detect the recombined K-Ras G12D allele by DNA PCR (Fig. 1C) .
K-Ras G12D expression results in early oral, gastric, and lung neoplasms
To investigate the differential effects of mutant K-Ras expression on signaling and tumorigenic progression in various tissues, mice were injected with 1 mg/mL tamoxifen for 5 consecutive days and monitored for morbidity or neoplastic lesions. More than 90% of Cre-ERT2;K-Ras G12D mice developed oral papillomas at the mucocutaneous junction within 4 weeks after tamoxifen treatment ( Fig. 2A) . By 5 to 6 weeks, Cre-ERT2;K-Ras G12D mice exhibited a mean 30% reduction in body mass compared with monoallelic mice. Mice were humanely sacrificed at the moribund stage (5-6 weeks after tamoxifen) and subjected to necropsy. . Indicated tissues were harvested from Cre-ERT2;K-Ras G12D mice 2 weeks after tamoxifen treatment. DNA from tail before tamoxifen injection (tail pre-tam) served as a control. Both the wild-type ($620 bp) and Cre-recombined mutant Ras ($650 bp) alleles are detected using the primers indicated. C, mutant K-Ras G12D RNA expression in various tissues. Following HindIII restriction
Histopathologic analysis indicated the oral tumors to be benign in nature as reported previously (refs. 17, 32, 34; Fig. 2B ). In addition, stomachs from Cre-ERT2;K-Ras G12D mice were enlarged and exhibited raised irregular masses on the inner stomach surface (Fig. 2C) . Histopathologic analysis revealed the transformation of the nonglandular part of the stomach into gastric papillomas in all K-Ras
G12D
-expressing mice (Fig. 2D) . Gross examination of lungs from Cre-ERT2; K-Ras G12D mice revealed multifocal lesions on the lung surface (Fig. 2E) . Histopathologic analysis showed the development of epithelial hyperplasia and benign adenoma in K-Ras G12D lungs (Fig. 2F) . Finally, complete blood counts showed hyperplasia in myeloid and lymphoid compartments indicative of development of myeloproliferative disease (MPD) and leukemia in K-Ras
-expressing mice (Supplementary Fig. S1A ). The spleens were markedly enlarged in Cre-ERT2;K-Ras G12D mice ( Supplementary Fig. S1B ) by 5 to 6 weeks after injection. Lymphoid infiltration was observed in livers from Cre-ERT2;K-Ras G12D mice with an otherwise normal histology (Fig. 2G) . Pancreas and small intestines from K-Ras G12D -expressing mice also displayed normal histology (Fig. 2H and I) . Thus, global expression of K-Ras G12D resulted in oral papilloma, lung adenoma, gastric papilloma, and hematopoietic hyperproliferation, as described previously (15, 18, 32, 35) . The global expression of K-Ras G12D did not result in tumor formation in intestines, pancreas, liver (Fig. 2G-I) , or mammary gland (data not shown), as reported previously in some tissue-specific expression studies (36) (37) (38) . The rapid appearance of oral, lung, gastric tumor, and hematopoietic hyperproliferation, resulting in a moribund state within 5 to 6 weeks of oncogenic K-Ras induction, may have precluded the observation of more slowly arising neoplasms.
K-Ras
G12D expression activates Erk1/2 signaling in both K-Ras G12D -susceptible and -refractory tissues Expression of the K-Ras G12D allele resulted in activation of Ras/Raf/MAPK signaling in several tissues. Thus, elevated levels of Ras signaling markers pErk1/2 and pSTAT3 were detected in K-Ras G12D -susceptible oral, gastric, and lung tumor ( Fig. 3A-C; Supplementary Fig. S2 ). Likewise, K-Ras G12D -refractory tissues such as liver, pancreas, and small intestine from biallelic mice showed upregulation of pErk1/2 in comparison with littermate controls (Fig. 3D  and E) . Thus, the levels of activated pErk1/2 and pSTAT3 proteins do not explain the tissue-specific differences in susceptibility to tumor formation. Collectively, these data show robust activation of Erk1/2 signaling in both K-Ras G12D -susceptible and -refractory tissues from tamoxifen-treated Cre-ERT2;K-Ras G12D mice.
The oncogenic K-Ras G12D -refractory tissues retain upregulated pErk1/2 in the cytoplasm Because there were tissue-dependent differences in responsiveness to oncogenic K-Ras in the 5 to 6 weeks after tamoxifen injection, we investigated Ras-activated MAPK signaling in the K-Ras-refractory tissues such as pancreas, liver, and small intestine. We reasoned that these tissues may exhibit a blunted Ras signaling to prevent neoplastic progression. The Erk1/2 are key signal transducing kinases that are phosphorylated in response to activated Ras signaling. The nuclear translocation of pErk1/2 culminate in uncontrolled proliferation via phosphorylation and activation of several downstream targets including transcription factors such as Elk-1 and c-Myc (9-13). Interestingly, even though pErk1/2 staining was greatly elevated in pancreas, liver, and small intestine in Cre-ERT2;K-Ras G12D mice, it was largely localized to the cytoplasm in these tissues (Fig. 4A) . In contrast, K-Ras G12D -induced oral, gastric, and lung neoplasms displayed intense nuclear distribution of pErk1/2 (Fig. 4B) . Next, we looked at the expression of pElk-1, which G12D expression generates rapid oral, gastric, and lung neoplasms, but little tumorigenic effect in liver, pancreas, and small intestine. A, Cre-ERT2;K-Ras G12D mice develop oral papillomas within 4 to 6 weeks after tamoxifen injection. B, H&E staining of oral tumors indicates benign papilloma formation in tamoxifen-treated Cre-ERT2;K-Ras G12D mice. C, induction of K-Ras G12D results in gastric papillomas. An averagesized stomach and inner surface of stomach from tamoxifen-treated Cre-ERT2 mouse is shown. Stomachs obtained from Cre-ERT2;KRas G12D mice are enlarged and reveal growths on the inner surface. D, H&E staining of a nonglandular region of normal stomach and gastric tumor. E, lungs expressing oncogenic K-Ras G12D show multiple lesions (arrows) on the surface. F, H&E staining of lungs from tamoxifen-treated control (Cre) and biallelic mice. G, H&E staining of liver from tamoxifen-treated Cre-ERT2;K-Ras G12D mice illustrate lymphocytic (arrows) infiltration with otherwise normal histology. H, pancreas from Cre-ERT2;K-Ras G12D mice is histologically similar to controls (Cre-ERT2). I, Ki67 (brown) staining of small intestines (jejunum) from Cre-ERT2 and Cre-ERT2;K-Ras G12D mice show no significant difference (counterstained with hematoxylin). is a nuclear transcription factor phosphorylated by pErk1/2. In contrast to K-Ras G12D -induced oral, gastric, and lung neoplasms that expressed pElk-1 in the nuclei, there was negligible detection of pElk-1 in the K-Ras G12D -expressing liver, pancreas, and small intestine (Fig. 5A) . In addition, cMyc protein, which is stabilized following phosphorylation by activated Ras/Erk signaling, was significantly elevated in the K-Ras G12D -susceptible oral and gastric tumors but not in K-Ras G12D -refractory tissues (Fig. 5B) . The percentages of Myc-positive cells in oral and gastric papilloma were 45.4% and 33%, respectively, whereas no nuclear staining for Myc was observed in pancreas, liver, and small intestine. To test whether the nuclear accumulation of pErk1/2 in KRas G12D -susceptible tissues is an early event leading to neoplastic transformation, we harvested oral mucosa and stomach at an earlier time point of 1 week after tamoxifen injection. At this time point, there were no obvious neoplastic lesions in these tissues. The immunostaining revealed largely nuclear distribution of pErk1/2 in oral and gastric mucosa from Cre-ERT2;K-Ras G12D mice. As expected, pancreas harvested at 1 week after tamoxifen injection showed predominantly cytoplasmic distribution of pErk1/ 2 ( Supplementary Fig. S3 ). Collectively, these data show differential subcellular distribution of pErk1/2 in KRas G12D -susceptible and -refractory tissues. The largely cytoplasmic distribution of activated Erk kinases correlates with restricted pErk1/2 signaling in tissues that are refractory to K-Ras G12D -induced neoplastic progression in the 6-week time frame following K-Ras G12D expression.
K-Ras G12D expression induces tumor suppressor proteins in K-Ras G12D -susceptible tissues The Ki67 staining for proliferating cells indicated hyperproliferation in the K-Ras G12D -induced oral (Fig. 6A) , gastric, and lung tumors (not shown). Despite hyperproliferation, the differentiation pattern in the oral tumors was similar to normal oral mucosa as marked by distribution of the basal and differentiated cell markers, keratin 5 (K5) and keratin 13 (K13; Supplementary Fig. S4 ). Previous studies indicate that the oncogenic K-Ras-induced tumor suppressor response can vary depending on the tissue type and stage of tumor (21) (22) (23) . The tumor suppressor response has not been clearly defined in K-Ras G12D -induced oral and gastric papillomas. We hypothesized that the welldifferentiated and benign nature of K-Ras G12D -induced tumors was the result of a strong global tumor suppressor response. Indeed, Western blot analysis of oral tumor lysates from Cre-ERT2;K-Ras G12D mice showed an upregulation of tumor suppressors p16
Ink4a , p19 Arf , and p53 (Fig. 6B) . Similarly, gastric papillomas showed an upregulation of tumor suppressors p16
Ink4a , p53, p21 ( Supplementary Fig.  S5A ), and p19
Arf (data not shown). The relative expression of p16
Ink4a and p19 Arf in lungs was much lower than in oral and gastric papillomas (data not shown). This is in accordance with the recent report where the Cdkn2a (Ink4a/Arf) locus was shown to be downregulated in lung tumors (21) . We further assessed the relative distribution of proliferation markers and tumor suppressors using the oral papilloma model. Promyelocytic leukemia (PML), a marker of senescence induced by oncogenic Ras (39, 40) , was upregulated in the suprabasal cell layers of oral papillomas ( Supplementary Fig. S5B ). Immunofluorescence staining for tumor suppressors indicated more widespread induction of p19
Arf , p53, and p16 Ink4a across multiple layers of oral papilloma in comparison with limited Ki67/BrdUrd expression in the basal and lower suprabasal cell layers of oral tumors (Fig. 6C-E) . In contrast to oral papillomas, we did not detect a significant induction of tumor suppressors p19
Arf and p53 in the K-Ras G12D -refractory pancreas, liver, and small intestines ( Fig. 6F and G; Supplementary  Fig. S5C and S5D) . These results indicate a strong and widespread induction of tumor suppressors in KRas G12D -induced premalignant tumors. However, KRas G12D -refractory tissues that do not form neoplasms within 6 weeks of tamoxifen treatment do not elicit a potent tumor suppressor response.
DNA damage, senescence, and NF-kB responses are elicited in K-Ras G12D -induced neoplasms Some human premalignant tumors elicit a DDR following oncogenic stress (25) . However, in mouse tumor models, the DDR is not invariably observed in oncogene-activated tissues (17, 41) . We examined whether the DDR pathway is activated in K-Ras-induced oral, gastric, and lung tumors within the time frame of 5 to 6 weeks after tamoxifen injection. Histone variant gH2AX, a key DDR marker associated with DNA strand breaks, was found to be upregulated in oral, gastric, and lung benign lesions (Fig. 7A) . gH2AX was markedly upregulated in oral tumors across all cell layers (Fig. 7B and C) . Phosphorylated pATM, another marker of an activated DDR, along with proliferation marker Ki67 were elevated in oral tumors across basal and suprabasal cell layers (Supplementary Fig. S6 ). Collectively, our data show that K-Ras G12D -induced neoplastic lesions in mice elicit a widespread DDR.
Mutant Ras can induce cell senescence accompanied by a senescence-associated secretory phenotype (SASP; ref. 42) . We tested for the SASP in the K-Ras-induced tumors. Quantitative PCR on RNA from K-Ras G12D -induced oral and gastric tumors was used to assay interleukin (IL)-6, MIP-2 (functional homolog of human IL-8 in mice), granulocyte macrophage colony-stimulating factor (GM-CSF), MCP-1, and IL-1a expression. We also examined IL-6R and CXCR2, receptors for IL-6 and MIP-2, respectively. RT-PCR analysis indicated elevated mRNA levels of several proteins associated with the SASP response for oral and gastric papillomas ( Fig.  7D; Supplementary Fig. S7A ). On the basis of the induction of several inflammatory cytokines, we assayed for NF-kB signaling in K-Ras G12D -induced tumors. Phosphorylation of inhibitor of NF-kB kinases (IKKa/b) relieves cytoplasmic sequestration and induces nuclear translocation of NF-kB proteins. Western blot analysis showed upregulation of pIKKb (upper band) in oral, gastric (Fig. 7E) , and lung tumors (not shown), indicating activation of the canonical NF-kB pathway. NF-kB p65 (RelA), the predominant form of NF-kB in cells, was elevated in tumors ( Fig. 7E and F) . Further examination using an antibody that recognizes the nuclear localization signal (NLS) of NF-kB p65 showed nuclear distribution of p65 in oral papilloma across several cell layers (Supplementary Fig. S7B ). These data show the activation of the SASP response in K-Ras
G12D
-induced neoplastic lesions in vivo. There is also significant activation of NF-kB signaling in K-Ras
-induced premalignant tumors that does not require a concomitant inactivation of p53 as reported previously (27) .
Discussion
Mouse models of oncogenic K-Ras have revealed the tumorigenic potential of K-Ras in multiple organs. In one study, induction of K-Ras G12V driven by CMV-Cre and RERTn-Cre-ERT2 resulted primarily in lung adenoma, whereas in another study, expression of K-Ras G12D driven by Rosa26-Cre-ERT2 resulted in multiple tumor types (oral, lung, and myelodysplasia; refs. 16, 17) . Our data are more consistent with the latter study, as we observed premalignant neoplasms in the hematopoietic tissues, oral mucosa, stomach, and lungs ( Fig. 2A-F; Supplementary Fig. S1 ). In the 5-to 6-week time frame after K-Ras activation, we did not find any obvious tumor formation in intestine, liver, pancreas (Fig.  2G-I) , and mammary gland (data not shown) as has been reported in tissue-specific expression studies for some of these organs (36) (37) (38) . It is possible that if these mice were to live longer, they may have developed tumors in the refractory tissues. Recently, K-Ras G12D driven by epithelial promoter CK19 resulted in tumors in the oral cavity, stomach, lungs, and pancreas (18) . This study did not find any hyperproliferation in intestines, liver, and kidney where the CK19 promoter is active. Such results, coupled with our results, show tissue specificity in cellular responses to oncogenic Ras activation. Some tissues undergo immediate hyperproliferation, whereas others are unaffected or affected in a more delayed manner. The mechanisms for these differential effects remain unclear (16, 18) and could be due to several undetermined factors such as tissue-specific differences in Ras signaling levels, differential activation of downstream Ras targets, or tissue-specific differences in Ras anti-oncogenic responses.
Our study, designed to explore the mechanisms by which tissues respond differently to an oncogenic stimulus, reveals that a tissue-specific difference in the subcellular distribution of downstream Ras targets is one mechanism that might determine the tumorigenic response to mutant K-Ras. Thus, K-Ras G12D -induced oral, stomach, and lung neoplasms show predominantly nuclear pErk1/2 distribution indicative of activated mitogenic signaling (Fig. 4B) . In contrast, pancreas, liver, and small intestine that do not develop early neoplasms retain upregulated pErk1/2 largely in the cytoplasm (Fig. 4A ). Cell culture-based studies have shown that growth factorinduced nuclear translocation of pErk1/2 is essential for mitogenic signal transduction and cell-cycle entry (9) (10) (11) . But the effects of subcellular pErk1/2 distribution on tissuespecific cancer induction have not been reported earlier. It remains largely unclear why some tissues succumb to certain oncogenic mutations whereas others remain refractory. We propose that inadequate nuclear translocation of pErk1/2 results in limiting the mitogenic stimulus in oncogenic K-Ras-refractory tissues (Supplementary Fig. S8 ). The failure to observe phosphorylated Elk-1 and c-Myc (downstream nuclear targets of pErk1/2 and transcriptional inducers of mitogenic genes) in the nuclei of K-Ras-refractory tissues provides functional confirmation of the block in Ras/MAPK signaling in these tissues (Fig. 5) . Several proteins such as PEA-15, Sef, and MKP-3 have been identified that restrict the nuclear localization and activity of Erks (14, (43) (44) (45) . One or more of these potential anchoring proteins may limit the nuclear accumulation of pErk1/2 in the oncogenic K-Rasrefractory tissues.
The oncogene-induced tumor suppressor response is another key mechanism that restricts tumor progression. The tumor suppressor responses elicited in oncogenic K-Ras-driven oral and gastric tumors have not been investigated before (18, 32, 34) . Our data show the induction of tumor suppressors such as p53, p19
Arf , p21, and p16
Ink4a in oncogenic K-Ras G12D -driven oral and gastric tumors ( Fig. 6B; Supplementary Fig. S5A ). Further examination of the spatial expression of tumor suppressors indicated their expression across all cell layers in the oral tumors (Fig. 6C-E) . Similarly, the DDR was elicited across oral papillomas ( Fig. 7B; Supplementary  Fig. S6 ). The widespread induction of several tumor suppressors and DDR proteins in response to oncogenic K-Ras G12D likely explains the lack of malignant tumor formation in oral epithelium in our study and elsewhere (32, 34) . Interestingly, the K-Ras G12D -refractory tissues did not elicit a potent tumor suppressor response ( Fig. 6F  and G; Supplementary Fig. S5C and S5D) . Thus, uncontrolled replication following an oncogenic mutation appears to be an essential stimulus to induce a potent tumor suppressor response in tissues. Collectively, our in vivo data reveal a novel mechanism by which tissues may differentially respond to an oncogenic stimulus such as mutant K-Ras. The pErks are largely retained in the cytoplasm in tissues that remain refractory to mutant K-Ras transformation. Other tissues that develop early neoplasms have high nuclear pErk1/2 levels and full activation of nuclear targets of Ras/Erk signaling (Supplementary Fig. S8 ). The spatial regulation of Erks may be one of the mechanisms that determine the tissue-specific response to an oncogenic mutation. We speculate that, apart from Mek/Erk inhibitors, spatial control of Erks could serve as another node for therapeutic intervention in tissues with deregulated Ras/MAPK signaling.
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